|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
8954 Rio San Diego Drive, Suite 102, San Diego, CA 92108, US
|
|
GRI Bio is a clinical stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF), a serious disease with significant unmet need. The Company is also developing a pipeline of novel Type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI has the ability to fuel a growing pipeline.
|
GRI Bio, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used GRI Bio, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact GRI Bio, Inc. customer service number in your country click here to find.
Marc Hertz is the CEO of GRI Bio, Inc.. To contact Marc Hertz email at [email protected] or [email protected]. Or you may call +1.8583350655 or +1.6194001170
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.